retatrutide glp-1 retatrutide 40mg Pen | Triple G Weight Management | Premio Peptides Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Losing just 5% of body weight can reduce your risk of developing type 2 diabetes by 58%

These typically peak when you start treatment or youre stepping up your doses (titration) and improve as your body adjusts: Because Retatrutide also targets glucagon, this alters how it affects your body, resulting in a couple of side effects not usually seen with Zepbound: 1

The accessibility gap means that tirzepatides benefits may remain out of reach for those who could benefit most from its effects

No TGA-approved pharmacy can dispense it

Mounjaro is unique in that it acts on both the GIP and GLP-1 receptors

In its phase 3 TRIUMPH-4 study, the company reported that its new triple-agonist injection, retatrutide, produced an average 28.7% reduction in body weight over 68 weeks a result that surpasses even the blockbuster Zepbound